Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Vectibix (panitumumab by Year
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Rest of World (ROW) product sales ($M) ($M)
Amgen Vectibix (panitumumab: $571M in FY2025, up 8.6% from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vectibix (panitumumab — Metastatic Colorectal Cancer) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 571 | +8.6% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 526 | +0.6% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 523 | +5.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 497 | -5.5% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 526 | +12.2% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 469 | +9.6% | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 428 | +6.2% | Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗ |
| FY2018 | Dec 31, 2018 | 403 | – | Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗ |
Cite this data
StockData. (2026). Amgen Vectibix (panitumumab ($M), annual FY2018–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-vectibix-row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.